US7462605B2
(en)
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EA200601591A1
(ru)
|
2000-05-26 |
2007-02-27 |
Айденикс (Кайман) Лимитед |
Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
SI1633766T1
(sl)
|
2003-05-30 |
2019-06-28 |
Gilead Pharmasset Llc |
Modificirani analogi fluoriranih nukleozidov
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
NZ554442A
(en)
*
|
2004-09-14 |
2011-05-27 |
Pharmasset Inc |
Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
JP2008523082A
(ja)
|
2004-12-09 |
2008-07-03 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
抗菌活性および抗癌活性を有するヌクレオチド
|
GB0505781D0
(en)
*
|
2005-03-21 |
2005-04-27 |
Univ Cardiff |
Chemical compounds
|
DE102006037786A1
(de)
*
|
2006-08-11 |
2008-03-20 |
Resprotect Gmbh |
Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
|
DK2099461T3
(da)
*
|
2006-11-13 |
2012-07-02 |
Santaris Pharma As |
LNA Nukleoside Phosphoramidates
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
AU2014233579B2
(en)
*
|
2007-03-30 |
2016-06-23 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidate prodrugs
|
US7964580B2
(en)
*
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
GB0709791D0
(en)
*
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
FR2922551B1
(fr)
*
|
2007-10-17 |
2009-12-25 |
Univ Claude Bernard Lyon |
Prodrogues phosphoesters de la gemcitabine comme agents anticancereux
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EA201100851A1
(ru)
|
2008-12-23 |
2012-04-30 |
Фармассет, Инк. |
Аналоги нуклеозидов
|
EP2671888A1
(en)
|
2008-12-23 |
2013-12-11 |
Gilead Pharmasset LLC |
3',5'-cyclic nucleoside phosphate analogues
|
MX2011006891A
(es)
|
2008-12-23 |
2011-10-06 |
Pharmasset Inc |
Fosforamidatos de nucleosidos.
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
MX2012003126A
(es)
|
2009-09-21 |
2012-06-19 |
Gilead Sciences Inc |
Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
|
EP2552931B1
(en)
|
2010-03-31 |
2014-07-23 |
Gilead Pharmasset LLC |
Stereoselective synthesis of phosphorus containing actives
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
AP3584A
(en)
|
2010-09-22 |
2016-02-09 |
Alios Biopharma Inc |
Substituted nucleotide analogs
|
GB201016855D0
(en)
*
|
2010-10-06 |
2010-11-17 |
Nucana Biomed Ltd |
Chemical compounds
|
US8841275B2
(en)
|
2010-11-30 |
2014-09-23 |
Gilead Pharmasset Llc |
2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
|
US9156874B2
(en)
|
2011-01-03 |
2015-10-13 |
Nanjing Molecular Research, Inc. |
Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
|
US9095599B2
(en)
|
2011-01-03 |
2015-08-04 |
Nanjing Molecular Research, Inc. |
O-(substituted benzyl) phosphoramidate compounds and therapeutic use
|
RS54776B1
(sr)
*
|
2011-03-01 |
2016-10-31 |
Nucana Biomed Ltd |
Fosforoamidatni derivati 5-fluoro-2'-dezoksiuridina za upotrebu u tretmanu kancera
|
WO2012154321A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
BR112014006324B8
(pt)
|
2011-09-16 |
2019-02-12 |
Gilead Pharmassett Llc |
composição e seu uso para o tratamento de hcv
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
CH707029B1
(de)
|
2011-10-21 |
2015-03-13 |
Abbvie Inc |
Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
|
EP2583680A3
(en)
|
2011-10-21 |
2013-06-12 |
Abbvie Inc. |
Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
DK2794629T3
(en)
|
2011-12-20 |
2017-07-24 |
Riboscience Llc |
2 ', 4'-DIFLUOR-2'-METHYL-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
|
PT2794628T
(pt)
|
2011-12-20 |
2017-07-05 |
Riboscience Llc |
Derivados nucleosídicos 4¿-azido-3¿-fluoro substituídos como inibidores de replicação de arn de vhc
|
WO2013096680A1
(en)
|
2011-12-22 |
2013-06-27 |
Alios Biopharma, Inc. |
Substituted phosphorothioate nucleotide analogs
|
CN104321333A
(zh)
|
2012-03-21 |
2015-01-28 |
沃泰克斯药物股份有限公司 |
硫代氨基磷酸酯核苷酸前药的固体形式
|
NZ630805A
(en)
|
2012-03-22 |
2016-01-29 |
Alios Biopharma Inc |
Pharmaceutical combinations comprising a thionucleotide analog
|
KR101770246B1
(ko)
|
2012-03-28 |
2017-08-22 |
후지필름 가부시키가이샤 |
1-(2-디옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 염
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
WO2013177219A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
D-amino acid compounds for liver disease
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
SG11201407336PA
(en)
|
2012-05-25 |
2015-03-30 |
Janssen Sciences Ireland Uc |
Uracyl spirooxetane nucleosides
|
WO2013187978A1
(en)
*
|
2012-06-16 |
2013-12-19 |
Nanjing Molecular Research, Inc. |
Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
|
AU2013303534B2
(en)
|
2012-08-13 |
2016-06-30 |
Fujifilm Corporation |
Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and method for producing the same
|
CN103665043B
(zh)
|
2012-08-30 |
2017-11-10 |
江苏豪森药业集团有限公司 |
一种替诺福韦前药及其在医药上的应用
|
EP2900682A1
(en)
|
2012-09-27 |
2015-08-05 |
IDENIX Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
TR201809048T4
(tr)
|
2012-10-08 |
2018-07-23 |
Centre Nat Rech Scient |
Hcv enfeksiyonu için 2'-kloro nükleosit analogları.
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
SG10201510324YA
(en)
|
2012-11-16 |
2016-01-28 |
Univ Cardiff |
Process for preparing nucleoside prodrugs
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
MY172166A
(en)
|
2013-01-31 |
2019-11-15 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
US10034893B2
(en)
|
2013-02-01 |
2018-07-31 |
Enanta Pharmaceuticals, Inc. |
5, 6-D2 uridine nucleoside/tide derivatives
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
EP2970357A1
(en)
|
2013-03-13 |
2016-01-20 |
IDENIX Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
AU2014250762A1
(en)
|
2013-04-12 |
2015-10-29 |
Achillion Pharmaceuticals, Inc. |
Highly active nucleoside derivative for the treatment of HCV
|
WO2014193663A1
(en)
|
2013-05-16 |
2014-12-04 |
Riboscience Llc |
4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
|
CA2912682C
(en)
|
2013-05-16 |
2021-07-06 |
Riboscience Llc |
4'-fluoro-2'-methyl substituted nucleoside derivatives
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
PT3038601T
(pt)
|
2013-08-27 |
2020-06-30 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
EP3057976A1
(en)
*
|
2013-10-17 |
2016-08-24 |
Medivir Ab |
Hcv polymerase inhibitors
|
RU2016125213A
(ru)
*
|
2013-11-27 |
2017-12-29 |
АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи |
Нуклеотиды для лечения рака печени
|
EP3109245B1
(en)
|
2014-02-18 |
2018-01-03 |
FUJIFILM Corporation |
Method for producting thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate
|
JP6204223B2
(ja)
|
2014-02-19 |
2017-09-27 |
富士フイルム株式会社 |
チオピラノース化合物等の製造方法
|
CN103804446A
(zh)
*
|
2014-02-27 |
2014-05-21 |
苏州东南药业股份有限公司 |
一种3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯的制备方法
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
NO3119794T3
(xx)
*
|
2014-06-25 |
2018-03-10 |
|
|
EP3757112B1
(en)
*
|
2014-06-25 |
2023-06-07 |
Nucana PLC |
Gemcitabine prodrugs
|
WO2016012781A1
(en)
*
|
2014-07-22 |
2016-01-28 |
Nucana Biomed Limited |
Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
|
EP3572410B1
(en)
|
2014-08-25 |
2022-07-20 |
Medivir Aktiebolag |
Dioxolane analogues of uridine for the treatment of cancer
|
WO2016033164A1
(en)
|
2014-08-26 |
2016-03-03 |
Enanta Pharmaceuticals, Inc. |
Nucleoside and nucleotide derivatives
|
GB201417644D0
(en)
*
|
2014-10-06 |
2014-11-19 |
Nucana Biomed Ltd |
Method of separating phosphate diastereoisomers
|
TWI687432B
(zh)
|
2014-10-29 |
2020-03-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
CA2966033A1
(en)
*
|
2014-10-31 |
2016-05-06 |
Cocrystal Pharma, Inc. |
2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
TWI678373B
(zh)
*
|
2014-10-31 |
2019-12-01 |
日商富士軟片股份有限公司 |
硫代核苷衍生物或其鹽及醫藥組合物
|
WO2016073756A1
(en)
|
2014-11-06 |
2016-05-12 |
Enanta Pharmaceuticals, Inc. |
Deuterated nucleoside/tide derivatives
|
EP3683225A1
(en)
|
2014-11-28 |
2020-07-22 |
Nucana PLC |
New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
|
US9732110B2
(en)
|
2014-12-05 |
2017-08-15 |
Enanta Pharmaceuticals, Inc. |
Nucleoside and nucleotide derivatives
|
BR112017012859A2
(pt)
|
2014-12-15 |
2017-12-26 |
Univ Emory |
fosforamidatos para o tratamento do vírus da hepatite b
|
WO2016134058A1
(en)
|
2015-02-18 |
2016-08-25 |
Abbvie Inc. |
Combinations useful to treat hepatitis c virus
|
GEP20217282B
(en)
|
2015-03-06 |
2021-08-10 |
Atea Pharmaceuticals Inc |
β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
|
EP3279207B1
(en)
*
|
2015-04-03 |
2024-01-24 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
|
CN115837028A
(zh)
*
|
2015-05-14 |
2023-03-24 |
努卡那有限公司 |
癌症治疗
|
TWI687431B
(zh)
*
|
2015-06-22 |
2020-03-11 |
瑞典商米迪維艾克提伯拉公司 |
治療癌症之前藥
|
CA2997170A1
(en)
|
2015-09-02 |
2017-03-09 |
Abbvie Inc. |
Anti-viral tetrahydrofurane derivatives
|
CN106543252A
(zh)
*
|
2015-09-16 |
2017-03-29 |
博瑞生物医药(苏州)股份有限公司 |
核苷氨基磷酸酯类前药的制备方法及其中间体
|
ES2909419T3
(es)
|
2015-09-16 |
2022-05-06 |
Gilead Sciences Inc |
Métodos para el tratamiento de infecciones por coronaviridae
|
CN106478753A
(zh)
*
|
2015-09-16 |
2017-03-08 |
博瑞生物医药(苏州)股份有限公司 |
一种nuc‑1031单一异构体的制备方法和用途
|
CN106543220A
(zh)
|
2015-09-16 |
2017-03-29 |
博瑞生物医药(苏州)股份有限公司 |
氨基磷酸酯化合物及其制备方法和晶体
|
JP7038653B2
(ja)
*
|
2015-10-05 |
2022-03-18 |
ニューカナ パブリック リミテッド カンパニー |
併用療法
|
SG11201804774YA
(en)
|
2015-12-11 |
2018-07-30 |
NuCana plc |
Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
|
GB201522771D0
(en)
|
2015-12-23 |
2016-02-03 |
Nucana Biomed Ltd |
Crystalline form of a phosphate derivative
|
CA3008749C
(en)
|
2015-12-23 |
2024-01-02 |
NuCana plc |
Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin
|
US20190381084A1
(en)
|
2015-12-23 |
2019-12-19 |
Nucana Biomed Limited |
Combination therapy
|
EA201892448A1
(ru)
|
2016-04-28 |
2019-06-28 |
Эмори Юниверсити |
Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
|
GB201609600D0
(en)
*
|
2016-06-01 |
2016-07-13 |
Nucuna Biomed Ltd |
Cancer treatments
|
WO2017223421A1
(en)
|
2016-06-24 |
2017-12-28 |
Emory University |
Phosphoramidates for the treatment of hepatitis b virus
|
US10711029B2
(en)
|
2016-07-14 |
2020-07-14 |
Atea Pharmaceuticals, Inc. |
Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
|
BR112019003946A2
(pt)
|
2016-08-31 |
2019-05-21 |
Fujifilm Corporation |
agente antitumoral, reforçador do efeito antitumoral e kit antitumoral
|
HRP20220278T1
(hr)
|
2016-09-07 |
2022-05-13 |
Atea Pharmaceuticals, Inc. |
2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima
|
EP3595672B1
(en)
|
2017-03-14 |
2023-09-06 |
Gilead Sciences, Inc. |
Compounds for use in methods of treating feline coronavirus infections
|
JP2020518578A
(ja)
*
|
2017-05-01 |
2020-06-25 |
ギリアード サイエンシーズ, インコーポレイテッド |
(S)−2−エチルブチル2−(((S)−(((2R,3S,4R,5R)−5−(4−アミノピロロ[2,1−f][1,2,4]トリアジン−7−イル)−5−シアノ−3,4−ジヒドロキシテトラヒドロフラン−2−イル)メトキシ)(フェノキシ)ホスホリル)アミノ)プロパノエートの結晶形態
|
GB201709471D0
(en)
|
2017-06-14 |
2017-07-26 |
Nucana Biomed Ltd |
Diastereoselective synthesis of hosphate derivatives
|
CN109134568B
(zh)
*
|
2017-06-15 |
2022-11-22 |
北京美倍他药物研究有限公司 |
核苷磷酸酯/酰胺衍生物及其医药用途
|
TW201919648A
(zh)
|
2017-07-11 |
2019-06-01 |
美商基利科學股份有限公司 |
用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
|
EP3677267A4
(en)
*
|
2017-09-01 |
2021-06-02 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF
|
GB201715011D0
(en)
|
2017-09-18 |
2017-11-01 |
Nucana Biomed Ltd |
Floxuridine synthesis
|
CA3075645A1
(en)
|
2017-09-21 |
2019-03-28 |
Riboscience Llc |
4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
|
GB201720279D0
(en)
|
2017-12-05 |
2018-01-17 |
Nucana Biomed Ltd |
Anticancer compounds
|
TW201932119A
(zh)
|
2018-01-29 |
2019-08-16 |
日商富士軟片股份有限公司 |
膽道癌用抗腫瘤劑和膽道癌的處理方法
|
BR112020015745A2
(pt)
|
2018-02-02 |
2020-12-08 |
Maverix Oncology, Inc. |
Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina
|
AU2019216514A1
(en)
*
|
2018-02-02 |
2020-09-24 |
Maverix Oncology, Inc. |
Novel small molecule drug conjugates of gemcitabine derivatives
|
JP6810763B2
(ja)
*
|
2019-03-06 |
2021-01-06 |
ニューカナ パブリック リミテッド カンパニー |
がん治療
|
GB201904544D0
(en)
|
2019-04-01 |
2019-05-15 |
NuCana plc |
Anticancer compounds
|
CA3163424A1
(en)
|
2020-01-27 |
2021-08-05 |
Gilead Sciences, Inc. |
Methods for treating sars cov-2 infections
|
WO2021173713A1
(en)
|
2020-02-27 |
2021-09-02 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against covid-19
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
WO2021183750A2
(en)
|
2020-03-12 |
2021-09-16 |
Gilead Sciences, Inc. |
Methods of preparing 1'-cyano nucleosides
|
AU2021251689A1
(en)
|
2020-04-06 |
2022-11-17 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
AU2021281351A1
(en)
|
2020-05-29 |
2023-01-19 |
Gilead Sciences, Inc. |
Remdesivir treatment methods
|
CA3187821A1
(en)
|
2020-06-24 |
2021-12-30 |
Gilead Sciences, Inc. |
1'-cyano nucleoside analogs and uses thereof
|
WO2022031150A1
(ko)
*
|
2020-08-07 |
2022-02-10 |
주식회사 피노바이오 |
데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도
|
MX2023002195A
(es)
|
2020-08-27 |
2023-03-03 |
Gilead Sciences Inc |
Compuestos y metodos para el tratamiento de infecciones virales.
|
EP4320128A1
(en)
|
2022-03-02 |
2024-02-14 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|